Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act.  Funding for HCV and public health activities via appropriations.  Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.  S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C. Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; H.R. 6 - 21st Century Cures Act.  Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B. Coverage of pharmaceuticals, cost-sharing, and other access issues, H.R. 21st Century Cures Act; Implementation of Pub. L. No. 114-1448, the ACA; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.  S. 3056: CREATES Act of 2016.
HCR - Health Issues MMM - Medicare/Medicaid PHA - Pharmacy
34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
FOLEY HOAG LLP
1717 K Street, N.W., Suite 1200, Washington, DC, 20006, US
PAUL KIM PAUL KIM PAUL KIM